The aim of this paper was to investigate the effects of the CCK, a rec
eptor antagonist loxiglumide on food intake, hunger and fullness in hu
mans. A double blind, placebo controlled, cross-over test was carried
out, with subjects taking one loxiglumide or one placebo tablet three
times a day, 15 min before main meals or at comparable intervals. The
work was carried out at the Centre for Human Nutrition, Northern Gener
al Hospital, University of Sheffield, on 11 healthy, normal weight, ma
le and female volunteers. The following were measured: weighed-intake
measurement of food intake during drug and placebo treatment; laborato
ry test of food intake on day three of each treatment; hunger and full
ness ratings throughout this meal. A small, non-significant, increase
in food intake as measured by the weighed intake diaries (8577 +/- 636
vs 7895 +/- 569 kJ (2049 +/- 152 vs 1886 +/- 136 kcal); P = 0.17) was
seen during loxiglumide treatment, but no effect on food consumption
from the evening test meal was observed and no effect on feelings of h
unger and fullness before or after this meal was seen. These results d
o not support the hypothesis that, in the free feeding situation, endo
genously released CCK is involved in the reduction of food intake or i
nhibition of hunger. However, a different dose of route of administrat
ion or a larger group of subjects may reveal an effect of loxiglumide
on feeding in humans.